Cefuroxime Sodium for Injection

1. This product belongs to the third generation of cephalosporin, with a broad-spectrum antibacterial effect, and is stable against broad-spectrum beta-lactamases (including penicillinase and cephalosporinase) produced by various Gram-positive and Gram-negative bacteria. This product has a strong antibacterial effect on Enterobacteriaceae such as Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. Pseudomonas and Acinetobacter species such as Pseudomonas aeruginosa are less sensitive to this product. Cefuroxime has a good antibacterial effect on Haemophilus influenzae and Neisseria gonorrhoeae. This product has a poorer effect on Staphylococcus aureus and Staphylococcus epidermidis than the first and second generation cephalosporins. Methicillin-resistant Staphylococcus aureus and Enterococcus are resistant to this product, and various streptococci are highly sensitive to this product. Anaerobic bacteria such as Peptococcus, Peptostreptococcus and some Bacteroides are mostly sensitive to this product, and Clostridium difficile is resistant to this product. 2. The mechanism of action of this product is to achieve bactericidal effect by inhibiting the biosynthesis of bacterial cell wall mucopeptides.

The main ingredient of this product is cefuroxime sodium.

Lower respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections, meningitis caused by Streptococcus pneumoniae or Haemophilus influenzae, and simple gonorrhea caused by sensitive bacteria.

1. Common dosage for adults: 1-2g (1-2 bottles) once, once every 8-12 hours; for patients with severe infection, the dosage can be increased to 3-4g (3-4 bottles) once, once every 8 hours. For the treatment of uncomplicated urinary tract infection, 0.5g once, once every 12 hours. 2. Common dosage for infants and children aged 6 months and above: 50mg/kg per time, once every 6-8 hours. 3. Patients with renal impairment: Patients with renal impairment need to adjust the dosage according to the degree of impairment. After the first loading dose of 0.5-1g, the common dose for patients with mild renal impairment (endogenous creatinine clearance Clcr of 50-79ml/min) is 0.5g once every 8 hours, and 0.75-1.5g once every 8 hours in case of severe infection; the common dose for patients with moderate renal impairment (Clcr of 5-49ml/min) is 0.25-0.5g once every 12 hours, and 0.5-1g once every 12 hours in case of severe infection; the common dose for patients with severe renal impairment who need dialysis (Clcr of 0-4ml/min) is 0.5g once every 48 hours, or 0.25g once every 24 hours, and 0.5-1g once every 48 hours in case of severe infection, or 0.5g once every 24 hours. Patients on hemodialysis do not need to take additional doses after dialysis, but need to take the drug at the end of dialysis according to the above-mentioned dose and time. 4. This product can be dissolved in water for injection, sodium chloride injection, 5% glucose injection and then slowly injected intravenously. It can also be added to 10% glucose injection, electrolyte injection or amino acid injection and intravenously dripped for 30 minutes to 2 hours.

1. Allergic reactions such as rash, itching and drug fever, diarrhea, nausea, vomiting, loss of appetite, etc. 2. Mild increase in alkaline phosphatase and serum aminotransferase, temporary increase in blood bilirubin, blood urea nitrogen and creatinine, etc. 3. Anemia (including hemolytic anemia), portal cell reduction, eosinophilia or thrombocytopenia are rare. 4. Occasionally, headache, numbness, dizziness, vitamin K and vitamin B deficiency, and anaphylactic shock may occur. 5. Mucosal candidiasis may occur in very few patients. 6. Burning sensation at the injection site, cellulitis, phlebitis (for intravenous injection), pain, sclerosis and paresthesia, etc.

1. Patients who are allergic to this product or other cephalosporins are prohibited from using this product. 2. Breastfeeding women should stop breastfeeding when using this product.

Precautions for children: The safety and effectiveness of this product for children under 6 months old have not been determined. Precautions for pregnancy and lactation: 1. Animal experiments have not found that this product has any damage to reproductive capacity and the fetus, but the safety of medication during pregnancy is still unclear. Pregnant women should only use it when there is a clear indication. 2. A small amount of this product can be secreted into breast milk. Lactating women should stop breastfeeding when using this product. Precautions for the elderly: Elderly patients may have a bleeding tendency caused by vitamin K deficiency, but they should pay attention to issues such as dosage and dosing interval, and should use the drug with caution; elderly patients are often accompanied by renal impairment, so the dosage should be appropriately reduced or the dosing interval should be extended.

When used in combination with coumarins, there is a possibility of enhancing the effects of coumarins: nephrotoxicity has been reported when used in combination with diuretics such as furosemide, other cephalosporins and aminoglycoside antibiotics.

Seal and store in a cool, dark (avoid light and not exceeding 20°C) dry place.

Calculated as C13H12N5O5S2 0.5g

24 months

PKU HealthCare Corp., Ltd.

• Founded in:

  1993-05-18

• Address:

  No. 21, Fangzheng Avenue, Shuitu Town, Beibei District, Chongqing

• Tax NO.:

  91500000450533779H

• Registered Funds:

  595.987425 yuan

• Website:

  Log in to view

• Email:

  Log in to view